1.8 Outlook 2019
For 2019, UCB expects the continued growth of its core products driving company growth. UCB will also advance its strong development pipeline to offer potential new solutions for patients and complement existing pipeline assets with external opportunities.
2019 revenue is expected in the range of € 4.6–4.7 billion. Recurring EBITDA in the range of 27-29% of revenue, reflecting higher R&D investments. Core earnings per share are therefore expected in the range of € 4.40 – 4.80 based on an average of 188 million shares outstanding.
The figures for the outlook 2019 as mentioned above are calculated on the same basis as the actual figures for 2018.
The new era belongs to those who conceive and believe in the beauty of their ideas.